What’s new to treat PsA? Let’s discuss anti-IL-17A, Izokibep #ACR22 @RheumNow Abstract #0199 💪 Izokibep 40 v. 80 mg q2 weeks SQ v. placebo 💪 135 patients, 28 sites 💪 At 12 weeks, all patient reported outcomes and PsAID subdomains significantly improved (dose dependent)

Clinical pearl! Patient-reported treatment success in PsA assoc'd w/ control of arthritis, dactylitis, psoriasis, and health-related QoL. Top 3 pt-reported reasons for tx failure were pain, psoriasis and fatigue. Abs0393 #ACR22 @RheumNow https://t.co/F9RNI7EXcL https://t.co/7DcLaqUqnm

• Are We Meeting Patients' Treatment Goals with Guideline-Based Therapy for …

Rates of MACE and VTE with upadacitinib were infrequent and consistent with background rates in RA, PsA and AS patients. Factors associated with MACE/VTE: age>65, HTN, DM, smoking, history CV event/VTE Abs#0510 @RheumNow #ACR22 https://t.co/AjtJF0p3QK

Do you consider ttmt successful? Question Christeen et al. asked to 100+ PsA pts. 1/3 pts said no, they had > TJC, > SJC, > Pso & > dactylitis. Failure also w/: pain 24%, pso 15%, fatigue 12% and < ability to be active 9%. https://t.co/dQseCNSDBS Abstr #0393 #ACR22 @Rheumnow https://t.co/kGlmscsKL7

• Are We Meeting Patients&#039; Treatment Goals with Guideline-Based Therapy for …

Interesting observation: Late-onset PsA assoc'd w/ male sex, greater structural damage, higher frequency of arthritis, and greater loss of functionality (BASFI). Interestingly, shorter time of symptom duration to dx. Abs 0377 #ACR22 @RheumNow https://t.co/m15c37FltD https://t.co/3LRy4Ltde6

• Differences in Early-onset vs. Late-onset Psoriatic Arthritis: Data from the RE…

So does PsA affect your capacity to work? DISCOVER-2 analysis: It’s presenteeism, not absenteeism which is the issue PsA pts drag themselves into work, but treating them helps them actually do their job. We need to fund more rheumatologists! ABST0509 @RADoctor #ACR22 @RheumNow https://t.co/Jnac6mV9O5

@DiegoBenavent et al: Gender impacts disease outcomes in PsA and SpA. Women > BASDAI, >BASFI, > ASDAS, >ASDAS Hi, and > EQ-5D. Not so surprising considering higher ratio for Fibromyalgia in W ASDAS not asso w/ gender in AxSPA. https://t.co/kBxvAi5qZw Abstr #0381 #ACR22 @Rheumnow https://t.co/vxdtlKpT3l

• Most Disease Outcome Measures but Not ASDAS Are Influenced by Gender in Patient…

Dr Scher shares his algorithm Rx for #PsA in clinical practice #acrreview #acr22 ⁦@RheumNow⁩ https://t.co/0xB1KwpfW7